Načítá se...
A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease
Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (rhGAA) fails to completely reverse muscle weakness in Pompe disease. β2-agonists enhanced ERT by increasing receptor-mediated uptake of rhGAA in skeletal muscles. PURPOSE: To test the hypothesis that a β-blocker might reduce...
Uloženo v:
| Vydáno v: | Mol Genet Metab |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4755835/ https://ncbi.nlm.nih.gov/pubmed/26454691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymgme.2015.09.012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|